Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2003
03/13/2003WO2002046213A3 Methods and reagents for isolating angiogenic modulators
03/13/2003WO2002046211A3 Peptides derived from colostrinin
03/13/2003WO2002044381A3 Human vno receptor (r1)
03/13/2003WO2002044380A3 Master bone formation transcription factor: compositions and methods of use
03/13/2003WO2002044379A3 Transforming growth factor-beta-related molecules and uses thereof
03/13/2003WO2002044364A3 Polypeptides involved in immune response
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042456A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002042413A3 Methods and compositions involved in groucho-mediated differentiation
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002036829A3 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
03/13/2003WO2002036731A3 Human lysosomal acid lipase
03/13/2003WO2002036613A3 Regulation of human patched-like protein
03/13/2003WO2002034773A3 Streptococcal genes
03/13/2003WO2002033056A3 Regulation of human serine-threonine protein kinase
03/13/2003WO2002030465A3 Compositions that inhibit proliferation of cancer cells
03/13/2003WO2002026984A3 Potassium channel interactors and uses therefor
03/13/2003WO2002026822A3 Pumpcn compositions and uses thereof
03/13/2003WO2002026802A3 M32404, a novel human trypsin and uses thereof
03/13/2003WO2002024925A3 69109, a novel human tyrosine phosphatase and uses therefor
03/13/2003WO2002024920A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/13/2003WO2002024233A3 Control of nk cell function and survival by modulation of ship activity
03/13/2003WO2002024177A3 Methods of identifying inhibitory compounds and uses thereof
03/13/2003WO2002022686A3 Defensin-antigen fusion proteins
03/13/2003WO2002022661A3 NOVEL PDEs AND USES THEREOF
03/13/2003WO2002022154A3 Pharmaceutical compositions for sustained drug delivery
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002020757A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002018552A3 Regulation of human aminotransferase-like enzyme
03/13/2003WO2002017959A3 Immunosuppression using piceatannol and a calcineurin inhibitor
03/13/2003WO2002017949A3 Novel functions for dp214
03/13/2003WO2002016589A3 Human abc transporter family member and uses thereof
03/13/2003WO2002016551A3 Trance regulation of chondrocyte differentiation
03/13/2003WO2002016416A3 Diagnosis and treatment of cardiovascular conditions
03/13/2003WO2002015893A3 Treatment of wounds
03/13/2003WO2002014919A3 Optical fiber with large effective area, low dispersion and low dispersion slope
03/13/2003WO2002014487A3 Adeno-associated virus-mediated delivery of angiogenic factors
03/13/2003WO2002014471A3 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
03/13/2003WO2002014358A3 Novel secreted proteins and their uses
03/13/2003WO2002013866A3 Stimulating neutrophil function to treat inflammatory bowel disease
03/13/2003WO2002013799A3 Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof
03/13/2003WO2002012280A3 Compositions and methods for the therapy and diagnosis of colon cancer
03/13/2003WO2002012272A8 Therapeutic anti-melanoma compounds
03/13/2003WO2002012271A3 Treatment of microbial infections with bacterial proteins and peptides
03/13/2003WO2002011762A3 Methods and compositions for modulating tumor growth
03/13/2003WO2002011750A3 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
03/13/2003WO2002009732A3 Method and device for concentrating and stabilising conjugated oestrogens from the urine of mares
03/13/2003WO2002008401A3 Elongase genes and uses thereof
03/13/2003WO2002008284A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2002008278A3 Compositions and methods relating to lung specific genes
03/13/2003WO2002006340A3 Tetraspan protein and uses thereof
03/13/2003WO2002002639A3 Human ion channels
03/13/2003WO2002000913A3 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2
03/13/2003WO2002000690A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2002000242A8 Human papilloma virus treatment
03/13/2003WO2001097848A3 Vitronectin receptor antagonist pharmaceuticals
03/13/2003WO2001096598A3 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF
03/13/2003WO2001096376A3 Pro-apoptotic fragments of the dengue virus envelope glycoproteins
03/13/2003WO2001090146A3 57256 and 58289, human transporters and uses thereof
03/13/2003WO2001088103A3 Compositions and methods for tissue dedifferentiation and regeneration
03/13/2003WO2001081578A3 Novel proteins and nucleic acids encoding same
03/13/2003WO2001078578A3 Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac
03/13/2003WO2001073032A3 Compositions and methods for the therapy and diagnosis of prostate cancer
03/13/2003US20030051270 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
03/13/2003US20030051269 Nucleotide sequences coding polypeptides for use controlling propagation of fish
03/13/2003US20030051268 CYT28 serpentine receptor disruptions, compositions and methods relating thereto
03/13/2003US20030051263 Genetic inhibition by double-stranded RNA
03/13/2003US20030051262 Generation of animal model for use in diagnosing and treating nervous system disorders; obtain animal, incubate with peptide, monitor brain activity, detect cellular degeneration, evaluate for brain disorder
03/13/2003US20030051260 Hmgi proteins in cancer and obesity
03/13/2003US20030051259 Packaging cells
03/13/2003US20030050469 Induction of a Th1-like response in vitro
03/13/2003US20030050467 Polypeptide for use in development of efficient analgesics
03/13/2003US20030050466 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of cancer or autoimmune diaseses
03/13/2003US20030050462 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050457 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/13/2003US20030050456 Nucleotide sequences coding polypeptide for use in the treatment of brain and psychological disorders
03/13/2003US20030050455 64 human secreted proteins
03/13/2003US20030050451 Peptide for use in the diagnosis and treatment of tumors
03/13/2003US20030050449 Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
03/13/2003US20030050446 Nucleotide sequences coding protein for use in the treatment of dietetics, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, learning defects, huntington's, alzheimer' and parkinson's diseases
03/13/2003US20030050443 Prostate specific secreted protein
03/13/2003US20030050442 62 human secreted proteins
03/13/2003US20030050440 Gene regulating aureobasidin sensitivity
03/13/2003US20030050436 Octapeptide bombesin analogs
03/13/2003US20030050435 Conotoxin protein for use as muscle relaxant and anesthetic
03/13/2003US20030050434 Peptide
03/13/2003US20030050344 Thyroid hormones or their salts in capsule or in swallowable uniform soft-gel gelatin matrices for treatment of hypothyroidism
03/13/2003US20030050331 Cytotoxic agents
03/13/2003US20030050320 A therapeutic agent for treating hepatitis C, based on polymerase inhibitory activity
03/13/2003US20030050283 Composition for the treatment and/or prevention of macular degeneration, method for its manufacture, and its use for treating the eye
03/13/2003US20030050273 Administering recombinant adeno-associated virus virions with a polynucleotide encoding a glial cell line-derived neutrotrophic factor polypeptide operably linked to expression control
03/13/2003US20030050271 Infecting the vasculature of an organ or a tissue other than a liver with a vector carrying genetic material of interest for a time under conditions which protect from ischemic damage
03/13/2003US20030050270 Antisense modulation of Inhibitor-kappa B Kinase-beta expression
03/13/2003US20030050269 Polynucleotides and polypeptides of the erythropoietin gene
03/13/2003US20030050267 Useful for treatment of cancers and cancerous cells which over-express alpha folate receptor (FR alpha ) compared to the normal cells of the same tissue
03/13/2003US20030050266 Anti-tumor effects of prostate carcinoma tumor antigen-1
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050264 Inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT(telomerase reverse transciptase) minimal promoter for upregulating, the expression of telomerase reverse transcriptase
1 ... 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 ... 3163